company's my of good XX and our last Thank you, call the had the year. why company, I confidence to year was lead and during Board marks background, week uniquely future. CEO iCAD. the believe March I and I X And everyone. call, Jeremy, afternoon, was This since of President and earnings shared qualified I named my in on I that first
and and alongside our clients talented this patients suite now, vision of cancer for for I'm I'm to and solutions, team, value be uphold most incredible then detection AI our and stakeholders. company. to and honored I pervasive creating shareholders lives our world's reiterate be the the stated to changing committed around personalized our partners, world Board, leading our Working As
management and to And prepared the uniquely this on going see say leverage to experience followed future we've The do. hope past of course growth. our you over team year, I you position their we to what for expertise deliver we we're as assembled the is company progress
into of get particularly risk our solutions being year a as our I take and company recap few market on detection we minutes want set in Before AI to solution opportunity. XXXX financials, a and solely focused light cancer to first
AI-powered cancer is iCAD detection in a leader global solutions.
providers the undetected match. and Suite, may be mission cancer Breast professionals might Suite reliably world because can't one poses has make create of hiding Breast is to finally life. it accurately its met Health wins enables Health move. identify With industry-leading medical our cancer where a and cancer where Profound when greatest hide hides, its it cancer to cancer threats The remaining Our when and to ProFound
by on and the The on ProFound of detection breast of breast to demographically number number density areas and breast number radiologists mammograms evaluation, The arterial and risk ProFound scores in levels latest evaluation years in identify risk density the detection, assessment suspicious is suite offers reporting. of the offers for and related heart focus patients, near-term X-year calcifications women's risk cardiovascular most provides cancer to breast Algorithmically breast diverse providers XD X The suite concern helping unique All solutions and three, more XX evaluation. XXX-degree one which cardiovascular serving images.
The arterial of developing geographically the on lesions four a breast making and scores.
The presence density actionable risk collection calcifications.
Powered ProFound cancer four, dataset. largest probability highest ProFound generalized standardizes suspicion or millions for from calcification elevated a Used one, anatomy assessment; and based solution or personalized relevant XD and ProFound areas: most two, and of number by raising than cancer solution the is X- it cancer. solutions assessment the quantity ProFound identifies intelligence density cases is of of image. comprised or built artificial innovations in cancer breast concern health of mammogram The risk next examining with concerns. of health for X heart elsewhere over correlate or solution in thousands proven and ProFound lifetime the body, available detection, simplifies countries.
the With We just XX on than patents, as I AI algorithms locations. over diverse in has the over XX datasets, train mammograms XX estimate detection, alone. last been data cancer global of million worldwide ProFound one described, years years iCAD regularly largest in secured for over more that clinical X XX studies. and used from our has And pulling we XXX most experience of completed
of differentiates algorithm using the its from competition AI as its as capabilities and leader models an set it positions iCAD's gets with that solution extensive research dataset continuously and company industry deep unmatched refines continually iCAD experience its better and the partners.
Data-as-a-Service X, earnings foundation, Phase Phase initiatives. As solution in Phase is leading organization breast increasing quarter premier XXXX as base, position investing our our call, by and X-phase transitioning growth a X, realigning implementing outlined AI into its our transformation. iCAD III platform-based by the a during third strengthening Software-as-a-Service,
X burn cash This our In operating QX operating million to 'XX cash Reduced as metric X, activities $X.X quarter. XXXX, which million $X.X in million XXXX good cash per including $X.X activities view relevant an was the operating $X EBITDA, we progress flow burn million. we nearly represents compared to made in cash from business of of burn a $XX.X XXXX burn. indicate cash of from of QX a reducing stabilize of improvement versus 'XX. of loss through a executing loss and million Phases
to XX% to subscription-based additional current reoccurring initiatives, We more cash about revenue manage shift the the later the talk in raise of We've end we the period subscription ARR affirm transition. pleased increase ARR summary, growth growth to X-year over through We'll of continued stabilized has growth call. QX in need this cycle. funding believe in pursue a burn not annual But does compounded ARR a to company achieved rate to 'XX. I'm and XX% had the annual total start in the since
sales Success. the announced North American team and joined Graham Operations; We Bill Vice a to Keyes Marketing, our growth. permanent his Officer, Vice and Global expanded as Senior and team Vice President addition Sales. President, our we President, Peter In Chief leadership expanded President accommodate Sales of expanding CFO, appointment December, of with Product and of shifted Senior role to Eric, of our leadership the Vice Customer us COO,
the seen "creating our announcements made We on where brand can't new value in proposition also good of additions. by and to cancer from a transitioning those progress tagline We upgraded resulting new you may Board our members, patient-centric a product hide". in recruiting recent have focus world
see Investors more can of You deck our icadmed.com. section our of investor for this via in upgrade the new website, available download brand
our not into models most to collaborations game-changing cash. and of influx put business an of Completing prioritizing, revenue. ProFound to detection partners, suite cancer commitment Xoft to also in expanding our the Announced a and this grow enabled scaling last world's partnership and burn cash immediately esteemed resulted And to focus divestiture us of with solutions. AI has exemplifying reduction sales the pervasive divestiture least, but company's creating suite personalized our the
including due The and channels, expanding phase launching and accounts to in III sales company's strengthen footprint. expanding indirect believe direct next significant U.S. Phase part of and had in in existing includes fiscal sales a through year begun declined XXXX, business reduction force XXXX. the initiatives in We geographic has our transformation and sales with that deepen growing iCAD's
XX QX in sales of XXXX. reps the had versus QX of in we As XXXX X U.S.,
After addressable national opportunity. outline over the believe lead sales a a X new performance adding members QX focused our discuss given additional opportunity, next, revenue I'll market to reps going to our large team I'm to thorough minutes new Since analysis accounts organization. reps years, which we of past and now large we on focused our on the business sales X large will few to take addressable market added call, growth. rep
is identified treatment greater X, to cancer, breast detection cancer respond to early likely diagnosing can rates. survival in When matters, result more and as Stage
breast fact, In Society, relative survival from the rate when X-year Cancer XX% is detected the cancer American to according early.
However, the Organization, Health in According World the to cancer cancer worldwide, growing. the cases incidence with cancer common diagnosed of lung XXXX. surpassing X.XX million breast cancer is most breast is recently worldwide new
seconds in lifetime, situation, XX% to their will X XX breast of tissue. every XX% recommended And miss cancer, missed with dense woman for women in and with Compounding missed in mammogram the who breast this women cancer X is to mammograms. with U.S. for a in the worldwide. XX% diagnosed breast of get regularly cancer screening up screening screened cancers are in breast those XX% women
relied family of inherited the of And diagnosed related models on history surprising assessment as family to fact, history the disease. with XX% Traditional are have direct XX% risk of when a factor most breast leading gene not risk women cancer and no in have disease XX% mutation. to
with As breast and lives. cancer detection save can greater help complex, more spot cancer accuracy radiologist AI is faster becoming increasingly
receiving distress stress. compared waiting system. and the in known suspected time & detect XD With biopsies images by are XX% diagnoses images systems radiologists Radiologist to hard to anxiety, migration or reading Burnout the radiologists and workload Xx and XD.
This Happiness are burnout of are at with results for not reported from more the overworked, similar interval as continuing undue weeks leads for recalls stress captured too, hundreds cancers Report images number delayed. the Lifestyle, unnecessary for is case patients radiologists continued Simultaneously, is or while of mention missed being to DBT or risen XD amount XX%. X to read fought to recalls increase for lead XD The cancers XXXX. systems, and have the are reading spending health Tomo false-positives of unnecessary to Her anxiously per to Medscape rates be to care geometric
routine average, with and have for back resulting cancer, found a in On only ultimately to workup from being diagnostic of recalled frustrated XX% process. confused a the mammogram women are patient screening the
more significant extend advanced when breast at in a cancer a patients years and that diagnosed throughout placed a instead, later And is payors diagnosis burden its stages. stage. early multiple Additionally, economic is missed upon
treating quality significant clinical health managing benefits, more intensive a breast of need treatment. among impact and costs caregiver earlier Increased patients cancer for and societal life, limit may reduce expensive cancer care burden. and associated and finding the Beyond have in health-related patients
costs. care diagnoses XXX,XXX savings a in years U.S. of for just the breast if calculates X were shifted women with $X.X would stage approximately of XX% and of diagnosed in across result year the cancer patient treatment iCAD X health earlier each billion
are care suspicious half AI-powered accuracy of a Breast and density risk evaluation. radiologist and in specificity improved times finding reading assessment Our with setting cancer new iCAD's cancer mammograms cut short-term suite, standard With may detection, lesions. ProFound in in Health be
Radiologists results benefit timely algorithm images, personalized results, built inclusive assessments many and risk plans. their from and of patients measured by benefit of from that density fact-based short-term screening receiving breast assessment standard millions an the objective upon inform
is create iCAD's above, cancer all when because mission noted As hide wins, world a lose. can't to we where cancer
received the the AI-powered The FDA and their as everywhere Breast and detect licensing. Health cleared risk ProFound breast accuracy single a CE benefit Canada has evaluate iCAD's For of Health the help health solutions earlier, suite by women cancer and image-based and and is well mammogram. with Mark as cancer from cardiovascular greater European communities, faster, of
As by the mammograms only and a thousands facilities of the the AI annual facilities Mammography December iCAD XXXX by has is are of using XX used of XX earlier, facilities providers of X United over Report solution, and base serving the XX.X as XX% or AI, million ProFound report, worldwide.
Based measured in ProFound Market U.S. the mammograms According ProFound Breast XXXX, markets, Yet believe the an countries. Act. of more opportunities, total Quality XX% AI years according millions for approximately a active than for million the research In is in Standards be growth to significant across number DBT, Outlook the to DBT our United opportunity represent installation to certified the Imaging growth.
Of FDA relative units using XXXX in are associated large of X,XXX market last to and patients. iCAD total X,XXX reading U.S. market. customer States. to X,XXX to conducted converted an Mammography and mammography noted of left room I leaving States solutions XD we estimates on XX% number alone, units may of available the
countries practice analog a We the XD markets, both additional mammography for AI exam. increase screening the also Western international exam a of radiologists as have to the implement more practice implemented using already European to in is each Furthermore, believe as rather DBT that growth of than radiologist those well digital each the single X from conversion programs, solutions planning performed number and countries current screening may mammograms there being or by opportunity mammography of countries. AI which read adopt having read in are
Since clearances, having solution FDA, detection in with releasing and by including iCAD built innovation Marks suite our the and X.X and available Health ProFound remained are network The most AI. newest first under released FDA our FDA-cleared the intelligence learning review iCAD deep currently the on breast of latest performing care has Breast to of highest XXXX, Health solutions ProFound product with neural version and solutions widely continuously in artificial improving Canada licenses. CE committed versions
data, regulatory heart iCAD curve Along we detection and and specificity, improve.
In options, deployment of recognized at improvements continue X.X make new technology, measuring deliver Per specificity XXXX, organizations sensitivity level of XX.X%. advocacy and industry calcification market-leading upon solution, cloud breast customers. the academic accessible under and health identifying detection arteries, in overall improve for the with leaders for breast concerns and iCAD area observed and iCAD strengthened sensitivity test partners to iterate the cardiovascular will version the the across and or has AUC cancer leader breast to solutions significant software ease AI-powered to new in highest with integration solutions, value more iCAD's research, our partnerships as implementation and
University, iCAD XX with With interoperable advancements Duke market than Pennsylvania vendors XX XXXX, are PACS with work share Institutet University, continued rise. and testing. distributors worldwide. and In the iCAD's of its solutions on clinical University on Indiana Our is and global intelligence Karolinska more artificial growing,
Health and has iCAD global and a co-development, mammography XX-year of new Health shortage. and women by worldwide.
iCAD as by reduce worldwide disparities and workflow for Additionally, to technology expanded potentially Google's increasingly Breast with with commercialization ProFound AI read countries of millions are XD expand challenging company's women. technology this Google suite enhance providers testing assessed workload X includes the access care ease separate to to partnership agreement the for and integration research development used mammograms health double conventional most radiologist radiologists become The workforce for there's where radiologist
secondary viable Leveraging as current introducing double alternative AI as to help a reading by radiology reader can more independent run departments iCAD efficiently.
XXXX, To make November channel as platform iCAD platform partners. and globe. cancer AI GE's new technology available release suite. implementation process partners system expanded across XXXX, GE made AI solution health new up detection Suite by of GE globally and and enabling into MyBreastAI ProFound to from more of Breast In into U.S. use in only plans X we to iCAD's iCAD and announced and customers we Health the for MyBreastAI the the all-in-one customers, an the integrated simplifying breast in solutions first Suite, has workflow algorithms partners, released sales
footprint. others iCAD integrations to Change aggregators Additionally, several such via several and new several and developed iCAD's under Healthcare, with distributors implement ProFound negotiation to expand cloud partnerships Ferrum, have AI marketplace further options, currently as and Blackford AI
the entity AI-read a countries and dedicated to will establishing in To Ghana is of imaging cancer to need RAD-AID, breast regions access in iCAD to that to highest. iCAD in medical nonprofit improve forward, in ProFound mortality Looking free radiology where cancer of RAD-AID the optimize mammograms. Guyana and iCAD are rates diagnosis plan partnership serving by equitable access Together, world. works detection improve and of to breast low-resource those with countries and XX bring start, the over to
to I'll now of Eric turn and our over call year-end financials. review XXXX a for detailed QX the
